Comparative Pharmacology
Head-to-head clinical analysis: BINIMETINIB versus MEKTOVI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BINIMETINIB versus MEKTOVI.
BINIMETINIB vs MEKTOVI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binimetinib is a reversible, non-ATP-competitive allosteric inhibitor of MEK1 and MEK2, blocking downstream ERK phosphorylation and signaling in the RAS-RAF-MEK-ERK pathway.
MEKTOVI (binimetinib) is a reversible, non-competitive inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2. It inhibits the MAPK/ERK pathway, which is activated in tumors with BRAF mutations.
45 mg orally twice daily.
45 mg orally twice daily, approximately 12 hours apart
None Documented
None Documented
Terminal elimination half-life is approximately 3.5–4 hours at steady state; no significant accumulation observed with twice-daily dosing.
Terminal elimination half-life is approximately 3.7 days (range 2.5–6.3 days) in patients with advanced solid tumors. This long half-life supports once-daily dosing.
Primarily hepatic metabolism with biliary-fecal elimination; unchanged drug in urine is negligible (<1%). In mass balance studies, ~70-80% of the dose is recovered in feces (mainly as metabolites) and <20% in urine (as metabolites).
Primarily fecal (94% of total radioactivity) with minimal renal excretion (4% of total radioactivity). Unchanged drug accounts for approximately 27% of the dose in feces.
Category C
Category C
MEK Inhibitor
MEK Inhibitor